ClinicalTrials.gg
CompletedNCT02207621Updated Apr 6, 2018Results posted

Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

A Phase 3 interventional study of AR-13324 Ophthalmic Solution 0.02% and Timolol maleate Ophthalmic Solution 0.5% BID in Ocular Hypertension and Open-angle Glaucoma, sponsored by Aerie Pharmaceuticals. Completed at 1 site in United States. Open to participants aged Up to 99 Years. Per ClinicalTrials.gov, last updated 2018-04-06.

Primary conditionGlaucoma, Open-AngleRegistry: Ocular HypertensionReclassifiedWhy we changed it
Registry
Ocular Hypertension — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glaucoma, Open-Angle
Why
  1. The study's listed conditions name Glaucoma, Open-Angle, a narrower term within Ocular Hypertension.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
756
Allocation
Randomized
Ages
Up to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing netarsudil in Glaucoma, Open-Angle — 3 open to participants now, 4 under way, none of them phase 3. netarsudil · Glaucoma, Open-Angle.

Enrollment
Largest of 17
756 · median 85
Started
2014
with 1 other
Phase 3
5 of 17
none open now
Registered
3rd of 17
by date
Lead sponsor
11 of 17
Aerie Pharmaceuticals

Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, this one has the largest enrollment, is one of 2 that started in 2014, is one of 5 in phase 3, and was the 3rd registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

3 of the 17 studies testing netarsudil in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About netarsudil

netarsudil: first FDA approval 2017 (RHOPRESSA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: Up to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing netarsudil in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

Evaluation of the ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution

03

Conditions studied

  • Ocular Hypertension
  • Open-angle Glaucoma

Browse trials for

Keywords

  • Glaucoma
04

In context

Glaucoma, Open-Angle Reclassified

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

This study's enrollment of 756 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.

Browse Glaucoma, Open-Angle studies →

Lead sponsor

Aerie Pharmaceuticals is the lead sponsor of 36 studies on the registry; none are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

First submitted before Aerie Pharmaceuticals became part of Alcon.

Compared within Glaucoma, Open-Angle, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ocular Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Up to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Subject inclusion criteria

  1. 0-2 years of age and 18 years or greater
  2. Diagnosis of open angle glaucoma or ocular hypertension
  3. Unmedicated (post-washout) intraocular pressure (IOP) >20 mm Hg and \< 27 mm Hg in the study eye at 2 qualification visits
  4. Corrected visual acuity in each eye equivalent to 20/200
  5. Able and willing to give signed (parent or guardian consent for pediatric patient) and follow study instructions

Subject exclusion criteria

Ophthalmic:

  1. Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure, or narrow angles. Note: Previous laser peripheral iridotomy is NOT acceptable.
  2. Intraocular pressure ≥27 mm Hg (unmedicated) in both eyes or use of more than two ocular hypotensive medications within 30 days of screening. Note: fixed dose combinations count as two medications.
  3. Known to any component of the formulations to be used (benzalkonium chloride, etc.), to topical anesthetics or beta-adrenoceptor antagonists.
  4. Previous glaucoma intraocular surgery or glaucoma laser procedures in either eye
  5. Refractive surgery in either eye.
  6. Ocular trauma in either eye within the six months prior to screening, or ocular surgery or non-refractive laser treatment within the three months prior to screening.
  7. Recent or current evidence of ocular infection or inflammation in either eye. Current evidence of blepharitis, conjunctivitis, or a history of herpes simplex or zoster keratitis at screening in either eye.
  8. Ocular medication in either eye of any kind within 30 days of screening.
  9. Clinically significant ocular disease in either eye (e.g., corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study, including glaucomatous damage so severe that washout of ocular hypotensive medications for one month is not judged safe.
  10. Central corneal thickness in either eye greater than 600 µm at screening.
  11. Any abnormality in either eye preventing reliable applanation tonometry of either eye.

    Systemic:

  12. Clinically relevant abnormalities (as determined by the investigator) in laboratory tests at screening which may impact the study.
  13. Known hypersensitivity or to beta-adrenoceptor antagonists (e.g., or bronchial asthma; abnormally low blood pressure or heart rate; second or third degree heart block or congestive heart failure; severe diabetes).
  14. Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study.
  15. Participation in any study within 30 days prior to screening.
  16. Changes of systemic medication that could have an effect on intraocular pressure within 30 days prior to screening, or anticipated during the study.
  17. Women of who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of . An adult woman is considered to be of childbearing potential unless she is one year or three months post-surgical sterilization. All females of childbearing potential must have a negative urine pregnancy test result at the screening examination and must not intend to become pregnant during the study..
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
756 participants (actual)

Study arms

  • Experimental
    AR-13324 Ophthalmic Solution 0.02% & placebo

    1 drop AR-13324 in the evening (PM) \& 1 drop placebo in the morning (AM) in both eyes (OU)

    Drug: AR-13324 Ophthalmic Solution 0.02% · Other: Placebo

  • Active comparator
    Timolol maleate Ophthalmic Solution 0.5% BID

    1 drop twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)

    Drug: Timolol maleate Ophthalmic Solution 0.5% BID

  • Experimental
    AR-13324 Ophthalmic Solution 0.02% BID

    1 drop AR-13324 twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)

    Drug: AR-13324 Ophthalmic Solution 0.02% BID

Interventions

07

What researchers measure

Primary outcomes

  1. Intraocular Pressure (IOP)

    The primary efficacy outcome is mean intraocular pressure (IOP)

    Time frame: 3 months

Secondary outcomes

  1. Extent of Exposure

    Exposure to study medication in days for all treatment groups

    Time frame: 12 Months

08

Results

Posted Apr 6, 2018

Participant flow

62 clinical trial sites participated in this study, of which 60 clinical trial sites enrolled participants. Screening started in June 2014. Enrollment started in July 2014. The last participant was enrolled in March 2015.

Participant flow — Overall Study
MilestoneAR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BIDAR-13324 Ophthalmic Solution 0.02% BID
Started251251254
Completed14620486
Not completed10547168
Withdrew: Adverse event7115132
Withdrew: Withdrawal by subject9913
Withdrew: Non-compliant331
Withdrew: Lost to follow-up103
Withdrew: Lack of efficacy1024
Withdrew: Disallowed concurrent medication252
Withdrew: Physician decision122
Withdrew: Protocol violation4106
Withdrew: Death200
Withdrew: Other(site,sponsor and subject request)215

Outcome measures

PrimaryIntraocular Pressure (IOP)

The primary efficacy outcome is mean intraocular pressure (IOP)

Time frame:
3 months
Reported as:
Mean · mmHg
Intraocular Pressure (IOP)
mmHgAR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BIDAR-13324 Ophthalmic Solution 0.02% BID
Day 1, 0800 hours23.51 ± 1.65423.45 ± 1.60123.50 ± 1.671
Day 1, 1000 hours22.31 ± 2.13122.18 ± 2.08922.26 ± 2.103
Day 1, 1600 hours21.56 ± 2.33821.61 ± 2.36921.49 ± 2.279
Day 15, 0800 hours19.01 ± 2.97918.25 ± 2.73618.20 ± 3.491
Day 15, 1000 hours17.74 ± 3.08917.49 ± 2.79616.91 ± 3.087
Day 15, 1600 hours17.37 ± 2.83017.59 ± 2.93516.28 ± 2.925
Day 43, 0800 hours19.37 ± 3.74918.08 ± 2.61418.57 ± 3.206
Day 43, 1000 hours18.10 ± 3.33517.31 ± 2.80517.09 ± 3.028
Day 43, 1600 hours17.88 ± 2.88817.25 ± 2.81316.58 ± 3.095
Day 90 (Month 3), 0800 hours19.43 ± 3.76118.21 ± 2.81918.66 ± 3.460
Day 90 (Month 3), 1000 hours18.18 ± 3.57117.52 ± 2.77717.81 ± 3.330
Day 90 (Month 3), 1600 hours17.73 ± 3.38617.67 ± 2.87917.08 ± 3.112
SecondaryExtent of Exposure

Exposure to study medication in days for all treatment groups

Time frame:
12 Months
Reported as:
Mean · days
Extent of Exposure
daysAR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BIDAR-13324 Ophthalmic Solution 0.02% BID
Extent of Exposure259.7 ± 133.34324.5 ± 90.73185.2 ± 144.56

Adverse events

Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AR-13324 Ophthalmic Solution 0.02% & Placebo2/251 (0.8%)17/251 (6.8%)198/251 (78.9%)
Timolol Maleate Ophthalmic Solution 0.5% BID0/251 (0%)12/251 (4.8%)96/251 (38.2%)
AR-13324 Ophthalmic Solution 0.02% BID0/253 (0%)7/253 (2.8%)213/253 (84.2%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventAR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BIDAR-13324 Ophthalmic Solution 0.02% BID
Coronary Artery DiseaseCardiac disorders2/2510/2511/253
Myocardial InfarctionCardiac disorders2/2511/2511/253
Atrial FibrillationCardiac disorders2/2510/2510/253
Atrial FlutterCardiac disorders1/2510/2510/253
BradycardiaCardiac disorders1/2510/2510/253
Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2510/2510/253
Malignant Melanoma in SituNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2510/2510/253
Myelodysplastic SyndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2510/2510/253
Prostate CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2510/2510/253
Postoperative IleusInjury, poisoning and procedural complications1/2510/2510/253
Most frequent other events
Showing 10 of 14
Most frequent other events
EventAR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BIDAR-13324 Ophthalmic Solution 0.02% BID
Conjunctival HyperaemiaEye disorders152/25135/251168/253
Cornea VerticillataEye disorders64/2512/25164/253
Conjunctival HaemorrhageEye disorders49/2512/25149/253
Instillation Site PainGeneral disorders45/25141/25145/253
Vision BlurredEye disorders27/2517/25144/253
Instillation Site ErythemaGeneral disorders14/2515/25132/253
Lacrimation IncreasedEye disorders19/2510/25125/253
Visual Acuity ReducedEye disorders22/2516/25122/253
Eye PruritusEye disorders14/2513/25120/253
Conjunctival OedemaEye disorders8/2510/25119/253

Baseline characteristics

The randomized population includes all subjects who were randomized to treatment. Baseline variables and demographic characteristics were summarized for this population.

Age, Continuous
Age, Continuous(Years)AR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BIDAR-13324 Ophthalmic Solution 0.02% BIDTotal
Mean65.3 ± 11.4863 ± 11.8164.1 ± 12.4664.1 ± 11.95
Sex: Female, Male
Sex: Female, Male(Participants)AR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BIDAR-13324 Ophthalmic Solution 0.02% BIDTotal
Female148150165463
Male10310189293
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BIDAR-13324 Ophthalmic Solution 0.02% BIDTotal
Hispanic or Latino414243126
Not Hispanic or Latino210209211630
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BIDAR-13324 Ophthalmic Solution 0.02% BIDTotal
American Indian or Alaska Native2002
Asian26614
Native Hawaiian or Other Pacific Islander0000
Black or African American697669214
White178166177521
More than one race0213
Unknown or Not Reported0112
09

Study locations

1 site
  • Aerie Pharmaceuticals
    Bedminster, New Jersey 07921, United States
10

References and documents

Publications

  • Mundorf T, Mah F, Sheng H, Heah T. Effects of Netarsudil on the Corneal Endothelium: Three-Month Findings from a Phase 3 Trial. Ophthalmol Glaucoma. 2020 Nov-Dec;3(6):421-425. doi: 10.1016/j.ogla.2020.04.014. Epub 2020 Apr 29. PubMed 33250082 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2014 to primary completion in Mar 2016, 20 months.

Results were first posted in Apr 2018, 2 years 1 month after primary completion. A results delay was requested in Jul 2016.

Of 47 industry-sponsored phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's 20 months is below that.

Counting every sponsor, half of 49 studies reached it within 26 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2014
First posted
Aug 4, 2014
StartActual
Jul 2014
Primary completionActual
Mar 2016
CompletionActual
Mar 2016
Results delay requested
Jul 11, 2016
Results first posted
Apr 6, 2018
Last update
Apr 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02207621
Responsible party
Sponsor
First posted
Aug 4, 2014
Start date
Jul 2014
Primary completion
Mar 2016
Completion
Mar 2016
Results posted
Apr 6, 2018
Last update
Apr 6, 2018

Study contacts

Theresa Heah, MD
study director · Aerie Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Netarsudil

Start the discussion